Hypertrophic Cardiomyopathy Panel
Use
This test is designed for individuals with clinical or suspected diagnoses of hypertrophic cardiomyopathy, those with a family member having hypertrophic cardiomyopathy without prior genetic testing, or individuals lacking access to specific variant information for a genetically-confirmed family member with hypertrophic cardiomyopathy. It aims to assist in confirming diagnosis and guiding treatment planning for patients by identifying genetic mutations associated with the condition.
Special Instructions
This test includes exome-wide CNV analysis, and offers options such as STAT testing and targeted family testing. Tests are validated following CAP and CLIA regulations, but are not FDA approved. Other procedural details like patient management and counseling should be strictly followed as per the institutional guidelines and informed consent requirements.
Limitations
The test's accuracy is contingent upon the quality of the clinical information provided. Tests have not been cleared or approved by the US FDA. Potential limitations include clinical interpretation challenges due to incomplete patient data or complex genetic information that might not capture every possible mutation or variation associated with hypertrophic cardiomyopathy.
Methodology
NGS
Biomarkers
Result Turnaround Time
2-3 weeks
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided